GW3965 HCl

Name: GW3965 HCl
Brand: Selleck Chemicals
SKU: S2630
Rating: 5 (29 reviews)

For research use only.

Catalog No.S2630

29 publications

CAS No. 405911-17-3

GW3965 HCl is a potent, selective LXR agonist for hLXRα and hLXRβ with EC50 of 190 and 30 nM in cell-free assays, respectively.

Selleck's GW3965 HCl has been cited by 29 publications

Science, 2018, 359(6376):684-688

PubMed: 29301957 ( click the link to review the publication )

Nature, 2016, 14;535(7611):303-7.

PubMed: 27383786 ( click the link to review the publication )

ACS Chem Biol, 2021, 16(1):136-149

PubMed: 33378170 ( click the link to review the publication )

Infect Immun, 2021, IAI.00788-20

PubMed: 33593888 ( click the link to review the publication )

Front Cell Dev Biol, 2020, 8:609090

PubMed: 33490072 ( click the link to review the publication )

Front Pharmacol, 2020, 27;11:375

PubMed: 32292349 ( click the link to review the publication )

Int Immunopharmacol, 2020, 90:107240

PubMed: 33310663 ( click the link to review the publication )

Clin Sci (Lond), 2020, 134(2):273-287

PubMed: 31957803 ( click the link to review the publication )

Neurotherapeutics, 2020, Apr 15

PubMed: 32297184 ( click the link to review the publication )

Nat Commun, 2019, 11;10(1):4621

PubMed: 31604910 ( click the link to review the publication )

EMBO Mol Med, 2019, 11(10):e10769

PubMed: 31468706 ( click the link to review the publication )

Cells, 2019, 8(12)E1601

PubMed: 31835444 ( click the link to review the publication )

J Neuroinflammation, 2019, 16(1):132

PubMed: 31255170 ( click the link to review the publication )

Neoplasia, 2019, 22(1):1-9

PubMed: 31751859 ( click the link to review the publication )

Am J Transl Res, 2019, 11(3):1498-1509

PubMed: 30972177 ( click the link to review the publication )

Redox Biol, 2019, 21:101069

PubMed: 30576926 ( click the link to review the publication )

Exp Neurol, 2018, 304:21-29

PubMed: 29447944 ( click the link to review the publication )

Immunol Cell Biol, 2018, 96(3):298-315

PubMed: 29345385 ( click the link to review the publication )

Mol Cell Endocrinol, 2018, 474:48-56

PubMed: 29454584 ( click the link to review the publication )

Biochem Cell Biol, 2018, 96(1):11-18

PubMed: 29024600 ( click the link to review the publication )

Exp Ther Med, 2018, 16(3):1814-1824

PubMed: 30186406 ( click the link to review the publication )

J Clin Invest, 2017, 127(2):583-592

PubMed: 28094767 ( click the link to review the publication )

Arch Toxicol, 2017, 91(1):271-287

PubMed: 27052460 ( click the link to review the publication )

Sci Rep, 2017, 7(1):2303

PubMed: 28536436 ( click the link to review the publication )
Cytokine, 2017, 91:30-37

PubMed: 27987394 ( click the link to review the publication )

Arch Virol, 2016, 161(9):2491-501

PubMed: 27357231 ( click the link to review the publication )

J Cell Biochem, 2016, 117(10):2272-80

PubMed: 26917453 ( click the link to review the publication )

FEBS Lett, 2015, 589(1):52-8

PubMed: 25436422 ( click the link to review the publication )

FEBS Lett, 2015, 589(1):52-8

PubMed: ( click the link to review the publication )

Purity & Quality Control

Choose Selective Liver X Receptor Inhibitors

Biological Activity

Description

GW3965 HCl is a potent, selective LXR agonist for hLXRα and hLXRβ with EC50 of 190 and 30 nM in cell-free assays, respectively.

Targets

hLXRβ ^[1] (Cell-free assay)	LXRα/SRC1 LiSA ^[1] (Cell-free assay)	hLXRα ^[1] (Cell-free assay)
30 nM(EC50)	125 nM(EC50)	190 nM(EC50)

In vitro

GW3965 recruits the steroid receptor coactivator 1 to human LXRα with EC50 of 125 nM in a cell-free ligand-sensing assay. ^[1] GW3965 shows a potent antagonistic activity against hLXRα and hLXRβ in cell-based assays with EC50 of 190 nM and 30 nM, respectively. Besides, GW3965 also sows excellent selectivity over other nuclear receptors. ^[1] In human islets, GW3965 (1 μM) reduces expression of selected pro-inflammatory cytokines including IL-8, monocyte chemotactic protein-1 and tissue factor. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
HEK293		NYXyRVRPOTBidV2=	M4ize\|IxKGi{cx?=	MW\BZ5RqfmG2aX;uJI9nKGi3bXHuJGxZWmGucHjhJIV5eHKnc4Pl[EBqdiCKRVuyPVMh[2WubIOgZ48u\XiycnXzd4lv\yCqdX3hckBTYFKjbIDoZUBifCBzMDD1UUBi\nSncjCyNEBpenNiYomgcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6	M1H6T\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MEC2PVA6Lz5{OECwOlkxQTxxYU6=
HEK293		NILTXGIyOCC3TR?=	M4HqV\|IxKGi{cx?=	MWPBZ5RqfmG2aX;uJI9nKHKjdDDMXHJj\XSjIHX4dJJme3OnZDDpckBJTUt{OUOgZ4VtdHNiY3:t[ZhxemW\|c3nu[{BpfW2jbjDSXHJidHCqYTDheEAyOCC3TTDh[pRmeiB{MDDodpMh[nlibIXjbYZmemG\|ZTDy[ZBwenSncjDn[Y5mKGG\|c3H5	M2fnOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MEC2PVA6Lz5{OECwOlkxQTxxYU6=
THP1	MoT6SpVv[3Srb36gZZN{[Xl?			MmPOTY5lfWO2aX;uJI9nKGOqb3zld5Rmem:uIHXm[ox2gCCrbjDUTHAyKGOnbHzzMEBGSzVyIE2gNE4xOSEQvF2u	M1jFRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NUi3OVc{Lz5zN{W4O\|U4OzxxYU6=
THP1	Mnn4SpVv[3Srb36gZZN{[Xl?		MW[xPEBpenN?	NYXqcldwUW6mdXP0bY9vKG:oIHPoc4xme3Sncn;sJIVn\my3eDDpckBVUFBzIHPlcIx{KGGodHXyJFE5KGi{czygSWM2OCB;IECuNFEh\|ryPLh?=	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzRzNkWyNUc,OTd2MU[1NlE9N2F-
COS7	MXLGeY5kfGmxbjDhd5NigQ>?		NVzoNXJIOTZiaILz	MUPB[49vcXO2IHHjeIl3cXS7IHH0JIh2dWGwIFzYVoJmfGFicnXj[ZB1d3JidILhcpNn\WO2ZXSgbY4hS0:VNzDj[YxteyCjZoTldkAyPiCqcoOgZpkhemWyb4L0[ZIhfHKjboPhZ5RqfmG2aX;uJIF{e2G7LDDFR\|UxKD1iMD6wNVUh\|ryPLh?=	M2TBelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NUi3OVc{Lz5zN{W4O\|U4OzxxYU6=
COS7	M37pT2Z2dmO2aX;uJIF{e2G7			M{XQ[mFkfGm4YYTpc44hd2ZiTGjSZoV1[SClbz30doFve2[nY4Tl[EBqdiCFT2O3JINmdGy\|IIfpeIghWliUYXzwbIEh[nlicnXwc5J1\XJidILhcpNi[3SrdnH0bY9vKGG\|c3H5MEBGSzVyIE2gNE4xOTVizszNMi=>	NVX6Om0{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe0NVY2OjFpPkG3OFE3PTJzPD;hQi=>
THP1	NXLjNWJjSW62aXnu[oxidW2jdH;yfUBie3OjeR?=		NXHUSYhkPiCqcoO=	M4\XUWFvfGmrbn\sZY1u[XSxcomgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCWSGCxJINmdGy\|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiTGDTMZN1cW23bHH0[YQhUUx4IIDyc4R2[3Srb36gZYZ1\XJiNjDodpMh[nliRVzJV2EtKEmFNUCgQUAxNjB{IN88UU4>	NV\EdJFoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi4NFA4PjdpPkG4PFAxPzZ5PD;hQi=>
THP1	MVTGeY5kfGmxbjDhd5NigQ>?			MnXQRYdwdmm\|dDDhZ5Rqfmm2eTDheEBISUxvbHnub4VlKGi3bXHuJGxZWmKndHGg[ZhxemW\|c3XkJIlvKFSKUEGgZ4VtdHNiYYPz[ZN{\WRiYYOgd5RqdXWuYYTpc44hd2ZiY3:tZYN1cX[jdH;yJJJm[3K3aYTt[Y51KGK7IF\SSXQh[XO\|YYmsJGVEPTBiPTCwMlAzPyEQvF2u	NGfBN4o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{[2OVg6Pyd-MUe2OlU5QTd:L3G+
RAW264.7	M{LpSWZ2dmO2aX;uJIF{e2G7		MV6yOEBpenN?	NGDwd25KdmS3Y4Tpc44hd2ZiW{PIYYNpd2ync4Tldo9tKGWoZnz1fEBqdiCvb4Xz[UBTSVd{NkSuO{Bk\WyuczDsc4Fl\WRid3n0bEBi[2W2eXzheIVlNUyGTDDh[pRmeiB{NDDodpMtKEWFNUCgQUAxNjB{OTFOwG0v	M1nwfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7N{G3N\|A1Lz5zOUexO\|MxPDxxYU6=
THP1	MoTwSpVv[3Srb36gZZN{[Xl?			NYTNeVRYW3SrbYXsZZRqd25ib3[gX\|NJZWOqb3zld5Rmem:uIHXm[ox2gCCrbjDoeY1idiCWSGCxJIZw[W1iY3XscJMhdG:jZHXkJJdqfGhiYXOtUGRNNCCHQ{WwJF0hOC5yM{Gg{txONg>?	Mm\3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh7N{OyPFgoRjF6OUezNlg5RC:jPh?=
CV1	NVvCTpFSTnWwY4Tpc44h[XO\|YYm=			Mn7NRY51[WexbnnzeEBi[3Srdnn0fUBifCCOWGLi[ZRiKGyrZ3Hu[EBjcW6maX7nJIRwdWGrbjDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIGSxN\|E4NWmwZIXj[YQhfHKjboPjdolxfGmxbnHsJIFkfGm4aYT5JIlvKGGocnnjZY4h\3KnZX6gcY9vc2W7IFPWNUBk\WyuczDjc{11emGwc3\lZ5Rm\CC5aYToJGdidDRvU2LDNUBjgSCudXPp[oVz[XOnIILldI9zfGW{IHHzd4F6NCCLQ{WwJF0hOC5yM{m4NUDPxE1w	NUHncXJbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCzOFUyODJpPkKwN\|Q2OTB{PD;hQi=>
THP1	MVnGeY5kfGmxbjDhd5NigQ>?			MXHB[49vcXO2IHHjeIl3cXS7IHH0JGdCVC2uaX7r[YQhcHWvYX6gUHhT[WyyaHGg[ZhxemW\|c3XkJIlvKFSKUEGgZ4VtdHNiYYPz[ZN{\WRiYYOgd5RqdXWuYYTpc44hd2ZiY3;hZ5RqfmG2b4KgdoVkenWrdH3lcpQh[nliRmLFWEBie3OjeTygSWM2OCB;IECuNFk4KM7:TT6=	NGCzUVI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{[2OVg6Pyd-MUe2OlU5QTd:L3G+
CV1	NV:5dGxKTnWwY4Tpc44h[XO\|YYm=			NUTqd406SW62YXfvcol{fCCjY4Tpeol1gSCjdDDMXHJidHCqYTDsbYdidmRiYnnu[Ilv\yCmb33hbY4h[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBVOTNzNz3pcoR2[2WmIITyZY5{[3KrcITpc45idCCjY4Tpeol1gSCrbjDh[pJq[2GwIHfy[YVvKG2xbnvlfUBEXjFiY3XscJMh[29vdILhcpNn\WO2ZXSge4l1cCCJYXy0MXNTSzFiYomgcJVkcW[ncnHz[UBz\XCxcoTldkBie3OjeTygTWM2OCB;IECuNUDPxE1w	NWD4dI1zRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCzOFUyODJpPkKwN\|Q2OTB{PD;hQi=>
SH-SY5Y	NGXQV5VHfW6ldHnvckBie3OjeR?=		NYLhVJliOjRiaILz	NV\xc4c2SWexbnnzeEBi[3Srdnn0fUBifCCqdX3hckBNYFKkZYThJIV5eHKnc4Pl[EBqdiCqdX3hckBUUC2VWUXZJINmdGy\|IHPvMZRz[W6\|ZnXjeIVlKHerdHigS4FtPC2OQlSgZYZ1\XJiMkSgbJJ{KGK7IHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfUwhTUN3MDC9JFAvOTNizszNMi=>	NVy5eolIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmyOlQ1QDFpPkG5NlY1PDhzPD;hQi=>
HepG2	NXzpVmtCTnWwY4Tpc44h[XO\|YYm=			M4HKNWVn\mWldDDvckBUWkWEUEHjJIdmdmViZYjwdoV{e2mxbjDpckBpfW2jbjDI[ZBIOiClZXzsd{whTUN3MDC9JFAvOjFizszNMi=>	NWn3Zm17RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi5O\|MzQDhpPkG4PVc{Ojh6PD;hQi=>
HuH7	MY\GeY5kfGmxbjDhd5NigQ>?			MXrB[49vcXO2IHHjeIl3cXS7IHH0JIh2dWGwIILlZ49u[mmwYX70JGxZWmKndHGgcIlo[W6mIHLpcoRqdmdiZH;tZYlvKGmwIHj1cYFvKEi3SEegZ4VtdHNiY3:teJJidnOoZXP0[YQhf2m2aDDmeZNm\CCJYXy0MWRDTCCkeTD0doFve2GldHn2ZZRqd25iYYPzZZktKEWFNUCgQUAxNjNzIN88UU4>	MlqzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh7N{OyPFgoRjF6OUezNlg5RC:jPh?=
SH-SY5Y	MkLDSpVv[3Srb36gZZN{[Xl?		MonrNlQhcHK\|	Mn;1RYdwdmm\|dDDhZ5Rqfmm2eTDheEBpfW2jbjDMXHJidHCqYTDlfJBz\XO\|ZXSgbY4hcHWvYX6gV2guW1l3WTDj[YxteyClbz30doFve2[nY4Tl[EB4cXSqIFfhcFQuVEKGIHHmeIVzKDJ2IHjyd{BjgSCudXPp[oVz[XOnIILldI9zfGW{IHflcoUh[XO\|YYmsJGVEPTBiPTCwMlMyKM7:TT6=	NXXmbFFbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmyOlQ1QDFpPkG5NlY1PDhzPD;hQi=>
CHO	MlvSSpVv[3Srb36gZZN{[Xl?			NFLSZ\|BC\2:waYP0JIFkfGm4aYT5JIF1KGi3bXHuJGxZWiCkZYThJJJm[2WydH;yJIV5eHKnc4Pl[EBqdiCFSF:gZ4VtdHNiYomgdoVxd3K2ZYKgZZN{[XluIFXDOVAhRSByLkSxJO69VS5?	Mm\kQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTdyM{SxNVkoRjF5MEO0NVE6RC:jPh?=
CHOK1	M{PsSWZ2dmO2aX;uJIF{e2G7		M4nx[FI1KGi{cx?=	MWPB[49vcXO2IHHjeIl3cXS7IHH0JGdidDRvdHHn[4VlKEy[UnLleIEhMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5iQ1jPT\|Eh[2WubIOgZYZ1\XJiMkSgbJJ{KGK7IHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfUwhTUN3MDC9JFAvPDJizszNMi=>	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ5N{[2OEc,OjV4N{e2OlQ9N2F-
THP1	NH3lfXdHfW6ldHnvckBie3OjeR?=			M3XlRmVn\mWldDDvckBCSkODMTDn[Y5mKGW6cILld5Nqd25iaX6gbJVu[W5iZHnm[oVz\W62aXH0[YQhXEiSMTDj[YxteyxiRVO1NEA:KDBwNEO0JO69VS5?	M2LTfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6OUezNlg5Lz5zOEm3N\|I5QDxxYU6=
CV1	NXnPc5R7TnWwY4Tpc44h[XO\|YYm=			MnfyRYdwdmm\|dDDhZ5Rqfmm2eTDheEBNYFKkZYThJIxq\2GwZDDibY5lcW6pIHTvcYFqdi2vZXTpZZRm\CC2cnHud4NzcXC2aX;uZYwh[WO2aY\peJkhcW5iYX\ybYNidiCpcnXlckBud26tZYmgR3YyKGOnbHzzJINwNXS{YX7z[oVkfGWmIIfpeIghT2GuND3TVmMyKGK7IHz1Z4ln\XKjc3WgdoVxd3K2ZYKgZZN{[XluIFXDOVAhRSByLkWwNVE6KM7:TT6=	M4ixTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyM{S1NVAzLz5{MEO0OVExOjxxYU6=
HuH7	M2P5TGZ2dmO2aX;uJIF{e2G7			Ml3URYdwdmm\|dDDhZ5Rqfmm2eTDheEBpfW2jbjDy[YNwdWKrbnHueEBNYFKjbIDoZUBtcWejbnSgZolv\GmwZzDkc41icW5iaX6gbJVu[W5iSIXIO{Bk\WyuczDjc{11emGwc3\lZ5Rm\CC5aYToJIZ2e2WmIFfhcFQuTEKGIHL5JJRz[W6\|YXP0bZZifGmxbjDhd5NigSxiRVO1NEA:KDBwNk[g{txONg>?	NYDpS3hVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi5O\|MzQDhpPkG4PVc{Ojh6PD;hQi=>
CV1	NX3pRYxMTnWwY4Tpc44h[XO\|YYm=			M1rmdWFod26rc4SgZYN1cX[rdImgZZQhVFiUYXzwbIEhdGmpYX7kJIJqdmSrbneg[I9u[WmwLX3l[IlifGWmIITyZY5{[3KrcITpc45idCCjY4Tpeol1gSCrbjDh[pJq[2GwIHfy[YVvKG2xbnvlfUBEXjFiY3XscJMh[29vdILhcpNn\WO2ZXSge4l1cCCJYXy0MXNTSzFiYomgcJVkcW[ncnHz[UBz\XCxcoTldkBie3OjeTygSWM2OCB;IECuO\|k1OzNizszNMi=>	NHe5NlY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEO0OVExOid-MkCzOFUyODJ:L3G+
CHOK1	NX3mOFYzTnWwY4Tpc44h[XO\|YYm=		MnrKNlQhcHK\|	NVLRdI5bSWexbnnzeEBi[3Srdnn0fUBifCCJYXy0MZRi\2enZDDMXHJidHCqYTCoeY5sdm:5bjDvdolocW5rIHX4dJJme3OnZDDpckBEUE:NMTDj[YxteyCjZoTldkAzPCCqcoOgZpkhdHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lJIF{e2G7LDDFR\|UxKD1iMT6zJO69VS5?	M4rUbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Nke3OlY1Lz5{NU[3O\|Y3PDxxYU6=
HepG2	MlTpSpVv[3Srb36gZZN{[Xl?			NYTj[5Y5TW[oZXP0JI9vKHS{aXfsfYNmemmmZTDhZ4N2dXWuYYTpc44hcW5iaIXtZY4hUGWyR{KgZ4VtdHNuIFXDOVAhRSB{LkCwNkDPxE1w	MkD6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh7N{OyPFgoRjF6OUezNlg5RC:jPh?=
HepG2	NIHGZplHfW6ldHnvckBie3OjeR?=	MmW2OVAxKG6P		NYrnOmh3UW6qaXLpeIlwdiCxZjCyMUg{NSh\|LTioNk1kcGyxcn:tN{0pfHKrZnz1c5JwdWW2aInsLYJmdnq7bDmoNkwzNWSrcHjlcplt\XSqeXypZY1qdm9rcILvdI95gSmyaHXufYwq[WOndHnjJIFkcWRvaX7keYNm\CC\|cnXidFFkKG2UTlGg[ZhxemW\|c3nvckBqdiCqdX3hckBJ\XCJMjDj[YxteyCjdDC1NFAhdk1?	NGrlNZI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEiwNFc3Pyd-MUi4NFA4Pjd:L3G+
HepG2	M3fZ[WZ2dmO2aX;uJIF{e2G7	MkDWOVAxKG6P		M13hR2lvcGmkaYTpc44hd2ZiMj2oN{0pOy1qKEKtZ4htd3KxLUOtLJRzcW[udX;yc41mfGi7bDni[Y57gWxrKEKsNk1lcXCqZX75cIV1cHmuKXHtbY5wMXC{b4DvfJkqeGinbonsLYFk\XSrYzDhZ4llNWmwZIXj[YQh\mG\|IH3SUmEh\XiycnXzd4lwdiCrbjDoeY1idiCKZYDHNkBk\WyuczDheEA2ODBibl2=	M4LiSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6OECwO\|Y4Lz5zOEiwNFc3PzxxYU6=
RAW264.7	MnLqSpVv[3Srb36gZZN{[Xl?	NHHCdIQyKHWP		Mnv0VoVlfWO2aX;uJI9nKEySUz3zeIlufWyjdHXkJIlPV1NiZ3Xu[UBmgHC{ZYPzbY9vKGmwIH3veZNmKFKDV{K2OE44KGOnbHzzJIV5eHKnc4PpcochVFiUYXzwbIEh[XRiMTD1UUBjgSCudXPp[oVz[XOnIILldI9zfGW{IHflcoUh[XO\|YYm=	MnXtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh6MEC3OlcoRjF6OECwO\|Y4RC:jPh?=
RAW264.7	MorvSpVv[3Srb36gZZN{[Xl?	NHG1XJIyKHWP		M1rG[mlvcGmkaYTpc44hd2ZiTGDTMZN1cW23bHH0[YQhdnWlbHXhdkBkdy2{ZYDy[ZN{d3JicnXs[YF{\SCocn;tJIlPV1NicILvcY91\XJiaX6gcY92e2ViUlHXNlY1NjdiY3XscJMh[XRiMTD1UUBjgSCUVD3QR3I>	NGTjPZo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEiwNFc3Pyd-MUi4NFA4Pjd:L3G+
HeLa	MlzBSpVv[3Srb36gZZN{[Xl?	M2GydFEhfU1?		NVnMUmdpUW6mdXP0bY9vKG:oIFzYVoJmfGFiU2XNU5lt[XSrb36gZpkhW1WPT{KgbY4hcHWvYX6gTIVN[SClZXzsd{BifCBzIIXNJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrcx?=	MmXpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh6MEC3OlcoRjF6OECwO\|Y4RC:jPh?=
HeLa	NVjjWVJtTnWwY4Tpc44h[XO\|YYm=	NH;ueYkyKHWP		NX7ZVHVKUW6mdXP0bY9vKG:oIFzYVoJmfGFiU2XNU5lt[XSrb36gZpkhW1WPT{OgbY4hcHWvYX6gTIVN[SClZXzsd{BifCBzIIXNJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrcx?=	M3nIdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6OECwO\|Y4Lz5zOEiwNFc3PzxxYU6=
HeLa	MXnGeY5kfGmxbjDhd5NigQ>?	NFHBT28yKHWP		MlvyTY5lfWO2aX;uJI9nKEy[UnHsdIhiKFOXTV;5cIF1cW:wIHL5JHNWVU9\|IHnuJIh2dWGwIFjlUIEh[2WubIOgZZQhOSC3TTDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN?	M1;HO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6OECwO\|Y4Lz5zOEiwNFc3PzxxYU6=
DAOY	NHv1O5hyUFSVIHHzd4F6			MY\xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhTEGRWTDj[Yxtew>?	Ml3aQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SJ-GBM2	MYLxTHRUKGG\|c3H5			NIrtVotyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1qtS2JOOiClZXzsdy=>	M{HN[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
A673	NVO5S2lSeUiWUzDhd5NigQ>?			MYrxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSTZ5MzDj[Yxtew>?	NH3BRnQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SK-N-MC	M3ntR5FJXFNiYYPzZZk>			NIm1V41yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1OSyClZXzsdy=>	M{LvdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-37	Mm[3dWhVWyCjc4PhfS=>			MoXwdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKEKWLUO3JINmdGy\|	M3XNelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB-EBc1	Mkf6dWhVWyCjc4PhfS=>			MXLxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVkJvRVLjNUBk\Wyucx?=	NUCzOFJZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-SH	MUPxTHRUKGG\|c3H5			NIPsUGlyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1UUCClZXzsdy=>	NHewcWc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
BT-12	M13mepFJXFNiYYPzZZk>			MoDVdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKEKWLUGyJINmdGy\|	Ml3mQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
OHS-50	Ml25dWhVWyCjc4PhfS=>			MnLldWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE:KUz21NEBk\Wyucx?=	M33WV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
RD	MYHxTHRUKGG\|c3H5			MWnxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWkRiY3XscJM>	NGO1S3k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
MG 63 (6-TG R)	NGC5dplyUFSVIHHzd4F6			NFS0RnlyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTVegOlMhMDZvVFegVkkh[2WubIO=	M1jve\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh30	MU\xTHRUKGG\|c3H5			M2PLVZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCUaEOwJINmdGy\|	MkHtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Rh41	NXi1SFV2eUiWUzDhd5NigQ>?			NHPMVVFyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUni0NUBk\Wyucx?=	M2rS[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	Skp2 / pEGFR / EGFR / pERK / ERK ; PubMed: 25184494 PLoS One GW3965 treatment downregulates SKP2 and EGFR protein levels in BxPC-3 and MIA-PaCa-2 cells. Downregulation of EGFR was concomitant with a downregulation of its own phosphorylation in BxPC-3 and MIA-PaCa-2 at 5 uM GW 3965. ERK1/2 and its phosphorylation were not statistically different in any of the cell lines. LXRα / LXRβ / ABCA1 / ABCG1; PubMed: 11604492 Mol Cell Biol Differentiated THP-1 macrophages were incubated for 48 h in RPMI medium plus 10% LPDS, Oxysterols [20(S)HC, 22(R)HC, or 22(S)HC, 2.0 μg/ml], synthetic LXR ligand (GW3965 or T1317, 0.1 to 10.0 μM), or RXR ligand (LG268, 50 nM).	25184494 11604492
Immunofluorescence	LAMP-1 / LDLR; PubMed: 23382078 Mol Cell Biol HeLa cells were cultured in 10% LPDS medium for 8 h and then treated with GW3965 (1 μM) for the indicated times. Cells were immunostained with LDLR and LAMP-1 antibodies. Nuclei were counterstained with DAPI (blue). Representative confocal images are shown. T, time; O/N, overnight. pRelA ; PubMed: 26635040 Haematologica Freshly isolated PDC (plasmacytoid dendritic cells) were treated for 24 h with 1 mM of GW3965 (GW), followed by TLR7 ligand, R848 (1 mg/mL) for 45 min. Phosphorylation of the NF-κB p65 (pRelA) subunit and its cellular localization were evaluated by confocal microscopy analysis. Results from a representative experiment out of 3 using PDC from 3 different donors.	23382078 26635040
Growth inhibition assay	Cell viability; PubMed: 25184494 PLoS One A, B, C, PDAC cells (BxPC-3, Mia-PaCa-2, and PANC-1 cell lines, respectively) show dose-dependent decreases in cell proliferation upon treatment with increasing GW3965 concentrations. EC50 calculations indicate that BxPC-3 and Mia-PaCa-2 cells are more sensitive to ligand treatment than PANC-1 cells.	25184494

In vivo

In mice, GW3965 at a dose of 10 mg/kg upregulates ABCA1 expression 8-fold and raises circulating levels of HDL by 30% with C_max of 12.7 μg/mL and t_1/2 of 2 hours. ^[1] GW3965 (10mg/kg) induces expression of ABCA1 and ABCG1 and shows potent antiatherogenic activity in both LDLR−/− and apoE−/− mice. ^[2] In male sprague-dawley rats, GW3965 reduces Ang II-mediated increases in blood pressure and decreases vascular Ang II receptor gene expression. ^[3] In Glioblastoma mouse model, GW3965 results in inducible degrader of LDLR-mediated LDLR degradation, increased expression of the ABCA1 cholesterol efflux transporter, and thus potently promotes tumor cell death. ^[5]

Protocol

Animal Research:^[1]	- Collapse Animal Models: C57BL/6 mice Dosages: ≤10 mg/kg Administration: Administered via p.o. (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	16 mg/mL warmed (25.86 mM)
	Water	Insoluble
	Ethanol	Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download GW3965 HCl SDF

Molecular Weight	618.51
Formula	C₃₃H₃₁ClF₃NO₃.HCl
CAS No.	405911-17-3
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	C1=CC=C(C=C1)C(CN(CCCOC2=CC=CC(=C2)CC(=O)O)CC3=C(C(=CC=C3)C(F)(F)F)Cl)C4=CC=CC=C4.Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
How to formulate the compound for mouse in vivo experiment?
Answer:
S2630 GW3965 HCl can be dissolved in 2% DMSO/30% PEG 300/dd H2O at 10 mg/mL as a homogeneous suspension. This vehicle is suitable for oral gavage to mice.

Related Liver X Receptor Products

SR9243 ^New

SR9243 is a potent and selective LXR inverse agonist.
Telaglenastat (CB-839) ^New

Telaglenastat (CB-839) is a potent, selective, and orally bioavailable glutaminase inhibitor with IC50 of 24 nM for recombinant human GAC. CB-839(Telaglenastat) inudces autophagy and has antitumor activity. Phase 1.
Setanaxib (GKT137831) ^New

Setanaxib (GKT137831, GKT831) is a potent, dual NADPH oxidase NOX1/NOX4 inhibitor with Ki of 110 nM and 140 nM, respectively. Treatment with GKT137831 suppresses reactive oxygen species (ROS) production. GKT137831 partly inhibits ferroptosis.
T0901317

T0901317 is a potent and selective agonist for both LXR and FXR, with EC50 of ~50 nM and 5 μM, respectively. T0901317 is a dual inverse agonist of RORα and RORγ with Ki of 132 nM and 51 nM, respectively. T0901317 significantly suppresses cell proliferation and induces apoptosis.
H 89 2HCl

H 89 2HCl is a potent PKA inhibitor with K_i of 48 nM in a cell-free assay, 10-fold selective for PKA than PKG,500-fold greater selectivity than PKC, MLCK, calmodulin kinase II and casein kinase I/II. H 89 2HCl induces autophagy.
Puromycin 2HCl

Puromycin 2HCl (CL13900) is an aminonucleoside antibiotic, which acts as a protein synthesis inhibitor.
Cyclosporin A

Cyclosporin A (Cyclosporine A, Cyclosporine, Ciclosporin, CsA) is an immunosuppressive agent, binds to the cyclophilin and then inhibits calcineurin with IC50 of 7 nM in a cell-free assay, widely used in organ transplantation to prevent rejection.
Dexamethasone

Dexamethasone (Hexadecadrol, Prednisolone F) is a potent synthetic member of the glucocorticoid class of steroid drugs, and an interleukin receptor modulator that has anti-inflammatory and immunosuppressant effects. Dexamethasone induces autophagy and mitophagy. Dexamethasone is tested in hospitalized patients with COVID-19 and is found to have benefits for critically ill patients.
Cyclophosphamide Monohydrate

Cyclophosphamide Monohydrate is a nitrogen mustard alkylating agent, it attaches the alkyl group to the guanine base of DNA, shown to crosslink DNA, causing strand breakage and inducing mutations.
Dabigatran (BIBR 953)

Dabigatran (BIBR 953) is a potent nonpeptide thrombin inhibitor with an IC50 of 9.3 nM in a cell-free assay.

Features:Dabigatran is a reversible, competitive, direct thrombin inhibitor.

Choose Your Country or Region

By Signaling Pathways

By product type

GW3965 HCl